Relpax

Relpax is a brand name of eletriptan, approved by the FDA in the following formulation(s):

RELPAX (eletriptan hydrobromide - tablet; oral)

• 
  Manufacturer: PFIZER IRELAND
  
  Approval date: December 26, 2002
  
  Strength(s): EQ 20MG BASE, EQ 40MG BASE ^[RLD]

Has a generic version of Relpax been approved?

No. There is currently no therapeutically equivalent version of Relpax available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Relpax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Indole derivatives
  Patent 5,545,644
  Issued: August 13, 1996
  Inventor(s): Macor; John E. & Wythes; Martin J.
  Assignee(s): Pfizer Inc.
  Compounds of the formula ##STR1## wherein n is 0, 1, or 2; X is hydrogen, chlorine, bromine or iodine; R.sub.1 is hydrogen; R.sub.3 is selected from hydrogen and C.sub.1 to C.sub.6 linear or branched alkyl; and R.sub.2 is as defined in the specification and the pharmaceutically acceptable salts thereof are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators. A process for forming indoles by transition metal catalyzed cyclization of a dihalogenated intermediate is also disclosed.
  
  Patent expiration dates:
  
  
  • December 26, 2016
    
    ✓ 
    Patent use: TREATMENT OF MIGRAINE WITH OR WITHOUT AURA
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Salts of an anti-migraine indole derivative
  Patent 6,110,940
  Issued: August 29, 2000
  Inventor(s): Harding; Valerie Denise & Macrae; Ross James & Ogilvie; Ronald James
  Assignee(s): Pfizer Inc.
  The present invention relates to hydrobromide salts of 3-(N-methyl-2(R)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl)-1H-indole having the formula (I): ##STR1##
  
  Patent expiration dates:
  
  
  • August 29, 2017
    
  
  

See also...

• Relpax Consumer Information (Drugs.com)
• Relpax Consumer Information (Wolters Kluwer)
• Relpax Consumer Information (Cerner Multum)
• Relpax Advanced Consumer Information (Micromedex)
• Relpax AHFS DI Monographs (ASHP)
• Eletriptan Consumer Information (Wolters Kluwer)
• Eletriptan Consumer Information (Cerner Multum)
• Eletriptan Advanced Consumer Information (Micromedex)
• Eletriptan Hydrobromide AHFS DI Monographs (ASHP)